Globally, GSK has an impressive community investment program. In 2009, GSK’s global community investment was valued at $229 million. Just over half of this comprises product donations. We focus our efforts on lymphatic filariasis (LF), HIV/AIDS and malaria as well as diarrhoea-related disease in children. GSK Australia is a part of this global program.

Key Achievements

Leader
Recognised as the leader in the Access to Medicines Index, an independent NGO/investor ranking of pharmaceutical companies.

1.1 bilion doses
Supplied 1.1 billion vaccine doses for prevention of serious diseases to nearly 80% of the developing world.

R &D
R&D investment into 12 diseases of particular importance for the developing world.

HIV/AIDS
349 million anti-retroviral tablets supplied to the developing world at preferential prices, including 279 million supplied by generic manufacturers licensed by GSK. GSK has supported 65 projects in 63 countries around the world in partnership with 54 organisations over the last eight years, through the Positive Action program.

Pricing
Reduced our not-for-profit prices for our HIV/AIDS medicines and anti-malarials for the fifth time since 1997; offered to 64 countries including sub-Saharan Africa and least developed countries.

Healthcare Infrastructure
Committed in 2009 to use 20% of profits from selling medicines in less developed countries, to strengthen healthcare infrastructure in the developing world.

600 million tablets
Committed to double the manufacturing capacity of our donated compound to the lymphatic filariasis elimination program to 600m tablets per year.

Health education
PHASE, a low-cost education program helping to reduce diarrhoea-related disease by encouraging school children to wash their hands, has reached over 375,000 children and their families globally. PHASE operates in eight countries - Bangladesh, Kenya, Uganda, Zambia, Nicaragua, Peru, Mexico and Tajikistan.

Industry collaboration
GSK, with five other Australian pharmaceutical companies, is an active member of the Collaboration for Health in PNG with the Australian Society of HIV Medicine and National Association of People Living with HIV. The program works with the Catholic Health system to address the rising rates of HIV in PNG by increasing health care capacity through mentoring visits and training, as well helping reduce the stigma associated with HIV positive people.

Fighting Malaria
The GSK Africa Malaria Partnership (AMP) supports the development of appropriate and effective behaviours that lead to better prevention and management of malaria, particularly for young children and pregnant women – the most vulnerable people affected by malaria.

GSK also worked in partnership with the World Health Organisation, UK Government and academia on a new malaria treatment, Lapdap, developed specifically for the developing world. A malaria vaccine is in clinical trials.